Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 09, 10:02 AMStifel upgrades Treace Medical to Buy, lifting TMCI 21% in early trading
Index
-
Market Cap
322.39M
Enterprise Value
357.07M
Income
-55.79M
Sales
203.35M
Book/sh
0.94
Cash/sh
0.61
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
450
IPO
Apr 23, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
1.59
P/B
5.23
P/C
8.10
P/FCF
-
EV/EBITDA
-
EV/Sales
1.76
Quick Ratio
1.66
Current Ratio
2.58
Debt/Eq
1.21
LT Debt/Eq
1.12
Option/Short
Yes / Yes
EPS (ttm)
-0.86
EPS next Y
-0.78
EPS next Q
-0.09
EPS this Y
10.82%
EPS next Y
5.69%
EPS next 5Y
9.62%
EPS past 3/5Y
-6.38% -61.76%
Sales past 3/5Y
14.46% 29.96%
EPS Y/Y TTM
-8.36%
Sales Y/Y TTM
-7.10%
EPS Q/Q
25.12%
Sales Q/Q
-3.91%
Insider Own
26.71%
Insider Trans
2.50%
Inst Own
49.75%
Inst Trans
-10.03%
ROA
-29.69%
ROE
-73.98%
ROIC
-42.74%
Gross Margin
79.55%
Oper. Margin
-24.38%
Profit Margin
-27.44%
SMA20
12.07%
SMA50
11.62%
SMA200
48.53%
Trades
Shs Outstand
65.53M
Shs Float
48.05M
52W High
5.25 -6.33%
52W Low
1.17 320.30%
Volatility
14.51% 8.44%
ATR (14)
0.41
RSI (14)
59.84
Beta
1.55
Rel Volume
1.82
Avg Volume
276.46K
Volume
101,265
Perf Week
9.28%
Perf Month
19.94%
Perf Quarter
9.04%
Perf Half Y
94.37%
Perf YTD
100.71%
Perf Year
46.35%
Perf 3Y
-20.81%
Perf 5Y
-77.03%
Perf 10Y
-
Prev Close
4.88
Price
4.92
Change %
0.77%
Consensus
Hold
Avg. Price Target
$6.17
Implied Upside
+25.5%
Analysts9incl. previous ratings
Rating Distribution3 Buy · 5 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 09, 2026Upgrade
SF logoSStifel
Hold → Buy$4.50 → $6.50+32.2%
Nov 07, 2025Downgrade
JPM logoJJP Morgan
Neutral → Underweight$5+1.7%
Nov 07, 2025Downgrade
BBTIG Research
Buy → Neutral
Feb 04, 2025Upgrade
BBTIG Research
Neutral → Buy$16+225.4%
Dec 31, 2024Initiated
LLake Street
Buy$14.50+194.9%
Dec 17, 2024Resumed
JPM logoJJP Morgan
Neutral$8+62.7%
May 16, 2024Downgrade
UBS logoUUBS
Buy → Neutral$16 → $6.50+32.2%
May 08, 2024Downgrade
TFC logoTTruist
Buy → Hold$17 → $7+42.3%
May 08, 2024Downgrade
SF logoSStifel
Buy → Hold$15 → $6+22.0%
May 08, 2024Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$15 → $5.50+11.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Treace John T.Chief Executive OfficerAug 20 '26Buy4.4439,944177,1767,388,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerAug 24 '26Buy4.3411,00047,7317,404,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerAug 21 '26Buy4.355,00021,7487,393,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerJun 10 '26Buy4.0229,430118,4267,353,263Jun 11 04:52 PM
Treace John T.Chief Executive OfficerJun 11 '26Buy4.0422,88792,5417,376,150Jun 11 04:52 PM
Treace John T.Chief Executive OfficerJun 01 '26Buy3.5650,000177,9157,323,833Jun 01 04:38 PM
Treace John T.Chief Executive OfficerMay 28 '26Buy3.0261,202184,8247,273,833May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 27 '26Buy2.8749,810143,1897,212,631May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 26 '26Buy2.794,50812,5767,162,821May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 14 '26Buy2.6261,750161,4957,158,313May 14 05:33 PM
Treace John T.Chief Executive OfficerMay 13 '26Buy2.4649,013120,5337,096,563May 14 05:33 PM
Treace John T.Chief Executive OfficerMay 12 '26Buy2.1743,00093,4787,047,550May 14 05:33 PM
Scanlan Sean F.Chief Innovation OfficerFeb 10 '26Option Exercise1.0516,87517,719706,474Feb 11 09:00 PM
Scanlan Sean F.Chief Innovation OfficerJan 21 '26Option Exercise0.7253,50038,520427,099Jan 23 09:30 PM
Treace Medical Concepts, Inc. engages in the designing, manufacturing, and marketing of orthopedic medical devices and biologic solutions. The firm offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
FounderMr. John T. Treace
Chief Financial OfficerMr. Mark L. Hair CPA
Chief Legal & Compliance Officer and Corporate SecretaryMr. Scot M. Elder J.D.
Chief Innovation & Marketing OfficerDr. Sean F. Scanlan Ph.D.
Chief Operations & Supply Chain OfficerMr. Terry W. Lubben